The AI Immunology Gamble: Merck's High Stakes Bet on Evaxion Merck & Company has made a significant investment in Evaxion A/S by staking a substantial portion of its shares and licensing one of Evaxion's vaccine candidates.
This move has sent shockwaves through the market, with Evaxion's stock price increasing 2% on the news. The implications of Merck's decision are far reaching.
Is this a vote of confidence in the potential of AI to revolutionize vaccine discovery, or simply a strategic play to bolster Merck's own pipeline?